Dale Gillham is chief investment analyst at Wealth Within Limited (AFSL 226347). He also serves as the head trainer at Wealth Within (RTO 21917). He has more than three decades of experience in the investment industry and is the author of How to Beat the Managed Funds by 20%. Dale's qualifications include an Advanced Diploma and a Diploma of Share Trading and Investment. He co-hosts the Talking Wealth Podcast, and his work has appeared in The Australian Financial Review, New York Business Journal, Wall Street Select and more. Connect with Dale Gillham on LinkedIn.
What the RBA’s next move could mean for your money
Would another rate cut be good news for your wallet - or a warning sign? Here's what the RBA's next move could mean for jobs, spending and your finances.
Trick or treat? How to think beyond the October Effect
The month of October has always had an ominous ring within financial circles. They call it the October Effect. This is the month of crashes, panics, and market meltdowns.
The best performers on the ASX this week
The best-performing sectors on the ASX included Materials, up more than 4%, followed by Energy and Utilities, so what about the week's top stocks?
The best and worst performing stocks of the week
The best performing stocks in the ASX top 100 this week include Pilbara Minerals up more than 15%, followed by IGO Limited, up more than 10%.
Four sectors set to benefit from Australia’s migration wave
Immigration is booming, and smart investors are profiting from it. Here's how to position your portfolio.
Why 5% deposit scheme is a debt trap
The government has just handed first home buyers what looks like a golden ticket, but it could be the fuse for a ticking time bomb.
Why building a portfolio is crucial in the AI era
There's more to investing in the age of artificial intelligence than gaining exposure to emerging technology. It could also be a matter of financial independence.
Domino’s plummeted 25% – should it be in your portfolio?
Domino's Pizza shares plunged on Wednesday after CEO Mark van Dyck resigned just eight months into the role. So is it time to buy or let this one go for good?
Monash IVF shares plunge after latest embryo mix-up
Monash IVF is back in the headlines, and for all the wrong reasons. Shares plunged 25% following news of a second embryo mix-up. For many investors, it's déjà vu.
The $200m deal that sent uranium stocks soaring
The Sprott Physical Uranium Trust's plans to scoop up US$200 million worth of physical uranium jolted a sector that's been quietly simmering for months.
